Edwards Lifesciences Stock: Wall Street's Uneven Reaction and 17.4% Upside Potential

Edwards Lifesciences (EW), a global leader in cardiac innovations with a $53.9 billion market cap, is gaining attention after strong Q2 results. The company saw an 11% increase in transcatheter aortic valve replacement and a 47% jump in mitral/tricuspid therapies, boosting its 2026 revenue outlook to $6.6 billion-$6.9 billion. With analysts expecting a 17.2% YOY EPS growth, Edwards topped estimates in three of the last four quarters. Piper Sandler raised its target to $101 with an 'Overweight' rating, suggesting an 8.1% upside. However, the stock fell 1.4% post-results. Wall Street is now evaluating Edwards' leadership in the healthcare sector and its potential for further growth. Markets will closely watch its ability to sustain momentum and innovate in transcatheter therapies. How will this impact investor sentiment and the broader healthcare sector?